Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2021-08-26 eCollection Date: 2022-03-01 DOI:10.2217/hep-2021-0003

Sarah Ronnebaum, Abdalla Aly, Dipen Patel, Fernando Benavente, Juan-David Rueda

引用次数: 0

Abstract

Aim: To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma.

Materials & methods: Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched.

Results: From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms.

Conclusions: Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.

Abstract Image

查看原文本刊更多论文

肝细胞癌推荐系统治疗试验的系统文献综述。

目的：确定和评估所有评估晚期肝细胞癌推荐治疗方法的试验的相似性。材料和方法：系统检索截至2021年2月任何时候发表的任何阶段的单臂和随机试验。结果：在审查的5677份记录中，50项试验被纳入审查，24项用于评估相似性。在一线（1L）环境中，与其他1L试验相比，评估索拉非尼的几项试验被注意到招募了疾病和/或表现状态更严重的患者；在二线（2L）环境中的试验通常是相似的。中位生存率是结论：评估推荐治疗的试验在很大程度上相似，适合于对几种疗效和安全性结果进行定量比较。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.